1. Imunon Targets ~80 OVATION 3 Patients in 12 Months, Cash Runway Extends to H2 2026
Imunon has set a critical operational target for its OVATION 3 clinical trial, aiming to enroll approximately 80 patients over the next 12 months. This aggressive enrollment goal comes as the company reports a significant extension of its financial runway, now projected to last into the second half of 2026. The dual an...